Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study
01/06/2019 | Author: MJ Hochmair et al.
Document ID: RD-110477
Accessible at: https://www.futuremedicine.com/doi/10.2217/fon-2018-0711
RELATED CONTENT
References & Footnote:
-
1.
Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
-
2.
Wu YL et al. Lancet Oncol. 2014;15(2):213-22.
-
3.
Yang JC et al. Lancet Oncol. 2015;16(2):141-51.
-
4.
Park K et al. Lancet Oncol 2016;17(5):577–89.
-
EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival.
-
*
LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (primary endpoint).
What is Afatinib (Giotrif®)?
Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 countries. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor mutation-positive (EGFR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]
*Afatinib is approved in more than 70 countries including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib®.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about Afatinib (Giotrif®)?
The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the Local Prescribing Information.
References:
-
[1]
GIOTRIF® Summary of Product Characteristics 2018.
-
[2]
Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
-
[3]
Wu YL et al. Lancet Oncol 2014;15(2):213–22.
-
[4]
Park K et al. Lancet Oncol 2016;17(5):577–89.